Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 04 2023
21 04 2023
Historique:
received:
13
12
2022
accepted:
18
04
2023
medline:
25
4
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
epublish
Résumé
We have previously shown that high expression of prolactin-induced protein (PIP) correlates with the response of breast cancer (BC) patients to standard adjuvant chemotherapy (doxorubicin and cyclophosphamide), which suggests that the absence of this glycoprotein is associated with resistance of tumor cells to chemotherapy. Therefore, in the present study, we analyzed the impact of PIP expression on resistance of BC cells to anti-cancer drugs and its biological role in BC progression. Expression of PIP and apoptotic genes in BC cell lines was analyzed using real-time PCR and Western blotting. PIP was detected in BC tissue specimens using immunohistochemistry. The tumorigenicity of cancer cells was analyzed by the in vivo tumor growth assay. Apoptotic cells were detected based on caspase-3 activation, Annexin V binding and TUNEL assay. The interaction of PIP with BC cells was analyzed using flow cytometry. Using two cellular models of BC (i.e. T47D cells with the knockdown of the PIP gene and MDA-MB-231 cells overexpressing PIP), we found that high expression of PIP resulted in (1) increased sensitivity of BC cells to apoptosis induced by doxorubicin (DOX), 4-hydroperoxycyclophosphamide (4-HC), and paclitaxel (PAX), and (2) improved efficacy of anti-cancer therapy with DOX in the xenograft mice model. Accordingly, a clinical study revealed that BC patients with higher PIP expression were characterized by longer 5-year overall survival and disease-free survival. Subsequent studies showed that PIP up-regulated the expression of the following pro-apoptotic genes: CRADD, DAPK1, FASLG, CD40 and BNIP2. This pro-apoptotic activity is mediated by secreted PIP and most probably involves the specific surface receptor. This study demonstrates that a high expression level of PIP sensitizes BC cells to anti-cancer drugs. Increased sensitivity to chemotherapy is the result of pro-apoptotic activity of PIP, which is evidenced by up-regulation of specific pro-apoptotic genes. As high expression of PIP significantly correlated with a better response of patients to anti-cancer drugs, this glycoprotein can be a marker for the prognostic evaluation of adjuvant chemotherapy.
Identifiants
pubmed: 37085653
doi: 10.1038/s41598-023-33707-w
pii: 10.1038/s41598-023-33707-w
pmc: PMC10121699
doi:
Substances chimiques
Doxorubicin
80168379AG
Glycoproteins
0
Membrane Transport Proteins
0
PIP protein, human
0
Prolactin
9002-62-4
perfosfamide
U880A4FUDA
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6574Informations de copyright
© 2023. The Author(s).
Références
Am J Cancer Res. 2018 Nov 01;8(11):2150-2164
pubmed: 30555735
Sci Rep. 2020 Jan 15;10(1):355
pubmed: 31942016
Breast. 2018 Jun;39:101-109
pubmed: 29656222
Protein Expr Purif. 2002 Jul;25(2):209-18
pubmed: 12135552
DNA Cell Biol. 2016 Oct;35(10):537-541
pubmed: 27602994
Mol Cell Biol. 2000 Aug;20(15):5503-15
pubmed: 10891490
Ann N Y Acad Sci. 1990;595:130-48
pubmed: 2142871
Int J Cancer. 2014 Apr 1;134(7):1617-29
pubmed: 24114735
Mol Cancer. 2010 Dec 15;9:314
pubmed: 21159167
J Cell Sci. 2017 Nov 15;130(22):3779-3787
pubmed: 29142064
Biochem Biophys Res Commun. 2015 Dec 25;468(4):850-6
pubmed: 26585492
Histopathology. 2005 Aug;47(2):195-201
pubmed: 16045781
Int J Cancer. 1995 Jan 17;60(2):216-20
pubmed: 7829219
Int J Mol Sci. 2018 Oct 04;19(10):
pubmed: 30287790
Ann Surg. 1980 May;191(5):599-603
pubmed: 7369822
Front Mol Neurosci. 2016 Jun 23;9:46
pubmed: 27445685
J Cell Physiol. 2012 May;227(5):2276-82
pubmed: 21809344
BMC Cancer. 2019 Aug 1;19(1):757
pubmed: 31370818
Breast Cancer Res. 2012 Jul 20;14(4):R111
pubmed: 22817771
Eur J Biochem. 1991 Mar 28;196(3):743-50
pubmed: 2013294
PLoS One. 2009;4(3):e4696
pubmed: 19262752
Eur J Cancer Clin Oncol. 1988 Feb;24(2):223-8
pubmed: 3356211
Breast Cancer Res Treat. 2004 Feb;83(3):249-89
pubmed: 14758095
Cancer. 1989 Jun 1;63(11):2156-61
pubmed: 2655863
Breast Cancer. 2000 Jan;7(1):49-55
pubmed: 11029771
Genes Dev. 1995 Jan 1;9(1):15-30
pubmed: 7828849
BMC Cancer. 2014 Jul 28;14:546
pubmed: 25070172
Biochim Biophys Acta. 2010 Jul;1804(7):1557-63
pubmed: 20406701
Biomed Pharmacother. 2016 Feb;77:161-6
pubmed: 26796280
Br J Cancer. 2010 Aug 10;103(4):524-31
pubmed: 20648017
Am J Pathol. 1983 Feb;110(2):105-12
pubmed: 6130702
J Natl Cancer Inst. 2018 Jun 1;110(6):677-681
pubmed: 29917141
Virchows Arch. 1994;425(5):459-65
pubmed: 7850069
J Natl Cancer Inst. 1979 Feb;62(2):239-47
pubmed: 283260
J Steroid Biochem. 1989;34(1-6):397-402
pubmed: 2626033
Int J Cancer. 1996 Nov 15;68(4):535-46
pubmed: 8945627
Cell Death Differ. 2006 Oct;13(10):1789-801
pubmed: 16429118
J Biol Chem. 2007 May 4;282(18):13791-803
pubmed: 17244621
Cancer Res. 1986 Jul;46(7):3728-33
pubmed: 3486713
Virchows Arch. 1996 Dec;429(6):365-9
pubmed: 8982381
Neoplasia. 2014 Apr;16(4):329-42.e1-14
pubmed: 24862759
Hum Pathol. 2013 Jul;44(7):1241-50
pubmed: 23332923
Cancer Chemother Pharmacol. 2009 Aug;64(3):607-14
pubmed: 19125251
Expert Opin Ther Targets. 2015 May;19(5):577-87
pubmed: 25828376
Cancer Biomark. 2021;32(2):207-219
pubmed: 34092611
J Exp Med. 1999 Jan 18;189(2):441-6
pubmed: 9892626
FEBS J. 2010 Jan;277(1):2-21
pubmed: 19843174
Apoptosis. 2006 Mar;11(3):337-46
pubmed: 16538383
J Dent Res. 1995 Sep;74(9):1543-50
pubmed: 7560414
Ann N Y Acad Sci. 1990;586:161-73
pubmed: 2192632
Apoptosis. 2003 Jun;8(3):229-36
pubmed: 12766483
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Int Med Res. 2013 Oct;41(5):1495-504
pubmed: 23934044
Int J Oncol. 2005 Mar;26(3):763-8
pubmed: 15703835
Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):508-514
pubmed: 29084054
Mol Biol Evol. 2019 Feb 1;36(2):393-411
pubmed: 30521052
Cell Signal. 2006 Apr;18(4):456-68
pubmed: 15970430
J Biol Chem. 2004 Jun 11;279(24):25535-43
pubmed: 15054096
Cancer Res. 1997 Feb 15;57(4):615-9
pubmed: 9044836
Cell Death Discov. 2019 Dec 4;5:148
pubmed: 31815003
Br J Cancer. 1999 Nov;81(6):1002-8
pubmed: 10576657
Crit Rev Clin Lab Sci. 2006;43(1):1-67
pubmed: 16531274
PLoS One. 2013 Jun 03;8(6):e62361
pubmed: 23755096
Am J Cancer Res. 2016 May 01;6(5):878-93
pubmed: 27293986
Int J Mol Sci. 2015 Sep 02;16(9):20969-93
pubmed: 26404249
J Exp Clin Cancer Res. 2010 Aug 07;29:107
pubmed: 20691103
Breast Cancer Res. 2007;9(6):R87
pubmed: 18086299
J Transl Med. 2022 May 13;20(1):211
pubmed: 35562750
Am J Obstet Gynecol. 1980 Sep 1;138(1):25-32
pubmed: 7416203
Biochim Biophys Acta. 2010 Apr;1802(4):396-405
pubmed: 20079433
Oncogene. 2005 Jul 14;24(30):4765-77
pubmed: 15870702
Am J Pathol. 1986 Jun;123(3):532-41
pubmed: 3717305
Mol Cell Proteomics. 2011 Feb;10(2):M110.003301
pubmed: 21048194
Oncol Lett. 2012 Mar;3(3):625-628
pubmed: 22740964
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Biol Chem Hoppe Seyler. 1991 May;372(5):325-9
pubmed: 1714742
J Biol Chem. 2007 Jun 8;282(23):16792-802
pubmed: 17324927